Sequenom Announces Distribution Agreement with Invitrogen for South and Central America
News May 01, 2008
Sequenom, Inc. has announced that it has entered into an agreement with Invitrogen Corporation under which Invitrogen will be the exclusive distributor for Sequenom's MassARRAY® systems and consumable products in Central and South America. Financial terms of the agreement were not disclosed.
"Among our top priorities is expanding our geographic reach and this agreement provides us with an entree into Central and South America, regions where we see a substantial opportunity but have had little exposure," said Sequenom's Senior Vice President, Sales & Marketing Michael Monko. "We are set to enter these regions utilizing the substantial resources available through Invitrogen and are pleased to be working with Invitrogen's first-rate sales team."
Separately, Sequenom announced the sale of its first MassARRAY system in South America. The system was sold to a sugarcane consortium to be used in biofuel research and development. Brazil is a leader in this area, producing the cheapest ethanol in the world. Sugarcane is a highly efficient raw material for the production of ethanol and is available in abundance in Brazil. Sequenom's technology will be used as part of an effort to engineer an even more productive line of sugarcane for ethanol production, the company has said.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.